Compare Abeona Therapeutics Inc (ABEO) vs Toronto-Dominion Bank (TD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Toronto-Dominion Bank — how do they compare? Abeona Therapeutics Inc trades at $6.71 (market cap $373.32M), while Toronto-Dominion Bank trades at $118.43 (market cap $200.57B). The key difference: Toronto-Dominion Bank is far larger — about 537.3× Abeona Therapeutics Inc's market cap, and Toronto-Dominion Bank pays a 2.67% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | TD | |
|---|---|---|
Market Cap | $373.32M | $200.57B |
Sector | Health | Financials |
52-Week High | $7.23 | $122.25 |
52-Week Low | $4.17 | $72.55 |
Enterprise Value | $228.22M | — |
Dividend Yield | — | 2.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
TD stock trades at $121.43, up 1.79% today, with a bullish technical signal from moving averages. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $1.74 surpassing the $1.63 estimate. Revenue grew to $61.28 billion in 2025, and the net income margin improved to 33.51%. Analysts maintain a buy consensus with a $153 price target, and the company recently increased its dividend.
The outlook is positive given strong profitability, dividend growth, and analyst support, but risks include volatile cash flows from operations and rising debt-to-asset ratios. The stock offers value with a P/E of 20.1 and robust ROE of 12.59%, though investors should monitor credit performance amid economic softness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →
